NasdaqGM - Nasdaq Real Time Price USD
TScan Therapeutics, Inc. (TCRX)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 4:37 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 6 |
| Avg. Estimate | -0.29 | -0.3 | -1.18 | -1.29 |
| Low Estimate | -0.34 | -0.36 | -1.29 | -1.7 |
| High Estimate | -0.24 | -0.24 | -1.07 | -1.11 |
| Year Ago EPS | -0.24 | -0.21 | -1.36 | -1.18 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 1.06M | 1.28M | 3.44M | 3.55M |
| Low Estimate | 500k | 500k | 2.1M | -- |
| High Estimate | 2.5M | 2.6M | 6.1M | 10M |
| Year Ago Sales | 3.89M | 7.21M | 21.05M | 3.44M |
| Sales Growth (year/est) | -72.70% | -82.20% | -83.70% | 3.20% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.45 | -0.29 | -0.26 | -0.28 |
| EPS Actual | -0.24 | -0.21 | -0.32 | -0.28 |
| Difference | 0.21 | 0.08 | -0.06 | 0 |
| Surprise % | 46.70% | 27.60% | -23.10% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.29 | -0.3 | -1.18 | -1.29 |
| 7 Days Ago | -0.29 | -0.3 | -1.18 | -1.29 |
| 30 Days Ago | -0.29 | -0.3 | -1.18 | -1.29 |
| 60 Days Ago | -0.29 | -0.3 | -1.18 | -1.29 |
| 90 Days Ago | -0.3 | -0.3 | -1.21 | -1.34 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TCRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -20.80% | -- | -- | 3.70% |
| Next Qtr. | -42.90% | -- | -- | 7.90% |
| Current Year | 13.20% | -- | -- | 2.50% |
| Next Year | -9.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.88% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | Wedbush: Outperform to Outperform | 8/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/13/2024 |
| Reiterates | Needham: Buy to Buy | 8/12/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/4/2024 |
| Initiated | BTIG: Buy | 5/16/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/14/2024 |
Related Tickers
MLYS Mineralys Therapeutics, Inc.
14.40
+3.75%
IMTX Immatics N.V.
9.88
+3.46%
IMCR Immunocore Holdings plc
34.38
+1.87%
CGEM Cullinan Therapeutics, Inc.
16.77
-3.45%
INZY Inozyme Pharma, Inc.
5.54
+7.57%
ELVN Enliven Therapeutics, Inc.
29.00
+3.50%
VIGL Vigil Neuroscience, Inc.
3.9600
-0.75%
TSBX Turnstone Biologics Corp.
0.4891
+3.58%
REPL Replimune Group, Inc.
11.53
+1.95%
SYRE Spyre Therapeutics, Inc.
32.76
0.00%